• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding.
 

Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding.

on

  • 432 views

Oncology Drug Funding is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid to late stage funding. Released in Sep 2013, ...

Oncology Drug Funding is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid to late stage funding. Released in Sep 2013, it is largest focused updated data available, covering 321 active cancer-focused investors, with past 10 years investment details in more than 500 oncology-focused companies.

Thus It will help to
- First innovative report to provide insights on several new strategic/financial investors willing to fund your company’s growth.
- Clearly identify - who will invest in your business and to which extent.
- Quickly navigate the complete profiles of new and focused Investors and their investment strategies.
- Identify the extent of funding in each round/series to meet your immediate and future needs.
- To design and negotiate on better financial plans to unlock the real value of innovation/assets.
- Directly get in touch with oncology focused Venture Partner through their Linkedin & E-mail ID.
- Explore Top Investors and eliminate your hours of digital search and data curation.
- Access to Numerous deals, structure & size to analyze true value of business model.

Statistics

Views

Total Views
432
Views on SlideShare
431
Embed Views
1

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 1

https://www.linkedin.com 1

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding. Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding. Document Transcript

    • PRIVATE EQUITY VENTURE CA SEED FUND GRANTSSERIES A IPOMERCHANT BANKERGRANTS MEZZANINE FINANCEPRIVATE EQUITY INVESTOR FINANCE SERIES B Opportunities IDENTIFY NEW FUNDING In Cancer Drug Development Copyright © HH Biotechnologies Pvt. Ltd.
    • A Comprehensive Intelligence Report On ONCOLOGYDRUG FUNDING 2013 REPORT COVERS ‘ONCOLOGY FOCUSED’ 321 502 947 3000+ Active Venture Capital Firm Profiles Investment Size | Criteria | Geographic focus Company Funding Details Includes past 10 years all Major Investment Rounds/Series Venture Partners Professional Profiles Linkedin & Email IDs of Partners | Personal Assistants Email IDs / Contact details Funding Round Details Details of Series A | B | C | D | E | F Included Infographics Based Summary Quick explore the Geographic distribution of VCs & their Geographic preference of funding w.r.t USA, Europe & Asia.6 pages VENTURE CAPITAL PRIVATE EQUITY PRIVATE EQUITY VEN SEED FUND G S MERCHANT BANKER GRANTSMEZZANINE FINANCE FINANCEIPO COMPREHENSIVE INTELLIGENCE SERIES2 Copyright © HH Biotechnologies Pvt. Ltd.
    • Oncology Drug Funding 2013 is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid to late stage fundings. It brings more authentic data under evaluation and is designed in a manner to keep knowledge intact, clear and precise. It also offers quick navigation on past 10 years major investments in the domain, thus allowing the information on fingertips’ and enhances your drug funding in-depth understanding. Further any information duplication is avoided to provide you with a clear and actionable intelligence. Full Coverage •    One of the largest updated data available, covering 321 active cancer-focused investors with their investment details in more than 500 oncology-focused companies. •    Includes Active Venture Capital, Private Equity and some notable Angel Investor firms. •    Also includes individual Investor Company profile, their core oncology venture partner team details & Investor funding preferences & past investments. Complete Cancer Drug Investors Intelligence •    With quick navigation tables, easily identify the top investors and their rich investment portfolio. •    Identify where large investors are investing in; and easily predict their funding preferences. •    Within oncology funding space, identify individual investor’s inclination towards funding drugs, diagnostics or risky technologies. Identify Top Investors •    Worldwide coverage of 500+ companies including cancer drug discovery/development, cancer diagnostic and cancer device/technology companies. •    Past 10 years complete funding data including various follow-up funding round/series details. •    Navigation Table to identify various funding Exits; through IPO or M&A activities. •    Quick all sets of funding from Seed to Growth are covered. All at One Place PRIVATE EQUITY ANGEL INVESTOR VENTURE CAPITA PRIVAT PRIVATE EQUITY NTURE CAPITAL D MERCHANT B SEED FU SEED FUND FINANCE PARTNER FINANCE GRANTS GRANTS MEZZANINE FINANCEIPO SERIES B SERIES A IPO GROWTH FUND SERIES A MERCHANT BANKER Largest Oncology Funding Database with Oncology focused Venture Partner’s Profiles. 3 ONCOLOGY DRUG FUNDING www.omicsx.com/reports.html
    • 12 Pages Infographics and Table, describes worldwide distribution of 321 Active Oncology Drug Funding Firms, with their country wise location, assets size, geographic investment preferences, ideal investment range and investment focus towards –early, mid and late stage funding. 33Pages Infographics and Tables, provides the complete insights of oncology funding pattern in past 10 years in 449 cancer focused companies, with geographic emphasis on investments in Exit (through IPO/M&A) and Active companies. Navigation tables for Exit and Active companies to provide list of all major funding rounds and their investors. 502 Pages contain 321 active oncology focused investor firms profilescoveringdetailsofcontact, Funds under management, Total investment portfolio Vs. cancer focused investment portfolio, geographicinvestmentpreference and investment range. Individual Firm management profiles of key oncology focused venture partners, e-mail/LinkedIn contact details. Firm’s all major oncology focused investments, series/rounds details with list of co-investors. SECTIONSECTION SECTIONSECTION SECTIONSECTIONReport Structures The complete 570 pages report is divided in three main sections for easy and quick navigation within report. Report sections contains thousands of interlinks to reach desired information on a single click. Apart, Table A.1, B.1 & B.2 are quite beneficial in narrowing down the choice of investors and identifying individual companies funding history. VENTURE CAPITAL PRIVATE EQUITY PRIVATE EQUITY VEN SEED FUND G S MERCHANT BANKER GRANTSMEZZANINE FINANCE FINANCEIPO COMPREHENSIVE INTELLIGENCE SERIES4 Copyright © HH Biotechnologies Pvt. Ltd.
    • How this Report can Help PRIVATE EQUITY ANGEL INVESTOR VENTURE CAPITA PRIVAT PRIVATE EQUITY NTURE CAPITAL D MERCHANT B SEED FU SEED FUND FINANCE PARTNER FINANCE GRANTS GRANTS MEZZANINE FINANCEIPO SERIES B SERIES A IPO GROWTH FUND SERIES A MERCHANT BANKER •    First innovative report to provide insights on several new strategic/financial investors willing to fund your company’s growth. •    Identify key venture partners contribution and strategic positions on Company’s Board. •    Detailed series co-investors details to identify best investors consortium for your needs. •    Access to Numerous deals, structure & size to analyze true value of business model. CXOs / Directors / VPs •    Identify new emerging players in drug funding, with their core team and funding preferences. •    De-risk the venture by getting real insights through a comprehensive picture. •    Infographics design with focused and interactive content, takes no time in filling knowledge gaps. •    Virtually cover all oncology focused funding deals occurs in past 10 years with their valuation sizes. Venture Partners •    Clearly identify - who will invest in your business and to which extent. •    Quickly navigate the complete profiles of focused Investors and their investment strategies. •    Identify the extent of funding in each round/series to meet your immediate and future needs. •    To design and negotiate on better financial plans to unlock the real value of innovation/assets. •    Directly get in touch with oncology focused Venture Partner through Linkedin & E-mail ID. Start-ups / Entrepreneurs •    Explore Top Investors and eliminate your hours of digital search and data curation. •    Spend quality time in analyzing finer funding details & decisions making. •    Identify paradigm shift in oncology drug funding; with 10 years of funding history covering 500+ companies and 3000+ Deals. •    Closely monitor wining deals and M&A activities by bringing more data under analysis. Analysts/ Consultants A Perfect Guide to provide complete Landscape on Oncology Drug Funding. 5 ONCOLOGY DRUG FUNDING www.omicsx.com/reports.html
    • VENTURE CAPITAL PRIVATE EQUITY P VENTURE C SEED FUND GRANTS SERIES A IPO MERCHANT BANKER GRANTSMEZZANINE FINANCE FINANCEIPO YES, I WOULD LIKE TO PURCHASE NOW Your Details: (Please use BLOCK CAPITALS) Title: Dr Mr Ms First Name:__________________________________________________ Last Name:___________________ Middle Name:____________________ Department:_________________________________________________ Position:_____________________________________________________ Company:____________________________________________________ Address:_____________________________________________________ ___________________________________________________________ ____________________________State/Province___________________ Country:_____________________Postcode/Zip:____________________ Tel:____________________________ Fax:_________________________ Mobile No:__________________________________________________ Email:_______________________________________________________ Please sign below to confirm your order Date: ___________ Signature______________________________________ Product Type: Intelligence Report (570 pages) Published by: HH Biotechnologies Pvt. Ltd. Product Code: ODF2013 Published in: September 2013 Single user price: $1495.00 Online Purchases: Click Here Payment To pay by Credit Card (PayPal, Visa, MasterCard, American Express), please, click ‘BUY NOW’ button on repot page http://omicsx.com/reports.html Mail this completed order form to: HH Biotechnologies Pvt. Ltd. 2760,Link Road, Nunhai Industrial Area, Near Rambagh, Agra-282006 India. E-mail: reports@omicsx.com Online: www.omicsx.com Fax back this form to USA +1 646 568 9962 Asia +91 562 228 1099 If you want to order Corporate License or Hard Copy, please, contact our Customer Service: contact@omicsx.com Stay Legal: Terms & Conditions In placing an order you agree not to hand-on or otherwise communicate this report in whole or part to any 3rd party whatsoever by any means or any access. You firstly pay for report, then I provide it. Our full terms and conditions related to the sale of this report please click here.... (All orders must be signed by authorised signatory) Sales Contact Numbers USA +1 646 513 4433 UK +44 203 608 3536 Asia +91 562 228 1122 Product Name: A Comprehensive Intelligence Report On - Oncology Drug Funding 2013 Order Form Copyright © HH Biotechnologies Pvt. Ltd.